A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01667133 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Interventions

DRUG: ponatinib - Phase 1
DRUG: ponatinib - Phase 2

Sponsor

Ariad Pharmaceuticals